Search PubMed⌕ Search

Biomedical subjects

P R Garner

Publications and source records attributed to P R Garner.

22 records · Page 2Linked to original sources

Treatment of severe hirsutism resulting from hyperandrogenism with the reverse sequential cyproterone acetate regimen.

Women with severe hirsutism resulting from hyperandrogenism often respond poorly to suppressive therapy aimed at decreasing adrenal or ovarian androgen production. Antiandrogens, such as cyproterone acetate, prevent androgens from expressing their activity at target sites by inhibiting the formation of the androgen/cytosol binding protein complex. Seven severely hirsute hyperandrogenic women were treated for six months with the reverse sequential cyproterone acetate regimen. Pretreatment plasma testosterone (T) levels were elevated in all subjects, and sex hormone binding globulin (SHBG) binding capacity was depressed. A free testosterone index, as assessed by the T/SHBG ratio, was markedly elevated. A marked and significant decrease in T levels and the T/SHBG ratio occurred during the first two cycles of treatment (p less than 0.01). Hirsutism grading assessed by the semiquantitative method of Ferriman and Gallwey did not change significantly until four months after the beginning of therapy but improved by six months of treatment. There was a marked antigonadotropic effect in terms of suppression of LH and FSH. The reverse sequential cyproterone acetate regimen produces rapid normalization of the plasma T, SHBG and free testosterone index, but resolution of the hirsutism is slower and requires several months of therapy.

Adult↗

The effect of human chorionic gonadotropin and estradiol-17beta on the maintenance of the human corpus luteum of early pregnancy.

The effect of exogenous human chorionic gonadotropin (HCG) and estradiol valerate (EV) on the maintenance of the corpus luteum of early pregnancy, assessed by serial estimations of serum progesterone and 17alpha-hydroxyprogesterone (17-OHP), was studied in 35 subjects following therapeutic termination of pregnancy by suction curettage before the tenth week of gestation. Continuous intravenous infusion of 50,000 International Units (I.U.) of HCG for 24 hours following termination of pregnancy delayed the decline of serum HCG levels, and 17-OHP levels were maintained at preoperative levels for the 24 hours of the infusion. Single intramuscular injections of 5,000 or 20,000 I.U. of HCG were ineffective. Administration of 25 mg. of EV intramuscularly immediately following therapeutic termination of pregnancy slightly retarded the decline of serum 17-OHP levels. The same treatment when administered in combination with the intravenous infusion of 50,000 I.U. of HCG completely prevented the ability of HCG to maintain serum levels of 17-OHP. These finding susggest an antagonism between estradiol and HCG in maintenance of the human corpus luteum during early pregnancy.

Chorionic Gonadotropin↗

Management of congenital adrenal hyperplasia during pregnancy.

OBJECTIVE: To provide an overview of the congenital adrenal hyperplasias (CAHs) and their management during pregnancy. METHODS: Pathways of steroid biosynthesis and inherited deficiencies of required enzymes are reviewed, and applications to prenatal diagnosis and treatment of affected fetuses are discussed. RESULTS: The CAHs are a group of inherited enzymatic defects of adrenal steroid biosynthesis. During pregnancy, maternal problems are confined to women with 21-hydroxylase deficiency, 11b-hydroxylase deficiency, and 3b-hydroxysteroid dehydrogenase deficiency because other adrenal enzyme deficiencies are incompatible with fertility. The interposition of the placenta on the hypothalamic-pituitary-adrenal axis has a major effect on clinical evaluation of CAH during pregnancy. Women with severe forms of CAH have decreased fertility rates because of oligo-ovulation, and successful conception requires a combination of good therapeutic compliance, careful endocrine monitoring, and often induction of ovulation. 21-Hydroxylase deficiency in the fetus can now be diagnosed accurately prenatally by endocrine testing and molecular genetic techniques. Prenatal diagnosis of 11b-hydroxylase deficiency in the fetus by endocrine testing is not as sensitive. Prevention of masculinization of affected female fetuses by corticosteroid suppression has been attempted in both 21-hydroxylase deficiency and 11b-hydroxylase deficiency CAH, with variable degrees of success. To date, no reports have been published of prenatal diagnosis or treatment of affected female fetuses with 3b-hydroxysteroid dehydrogenase deficiency CAH. CONCLUSION: Endocrine and genetic studies of CAH during pregnancy have improved the diagnosis and management.

Journal Article↗